List of Excipients in API PIRTOBRUTINIB
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing PIRTOBRUTINIB
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Eli Lilly and Company | JAYPIRCA | pirtobrutinib | 0002-6902 | CELLULOSE, MICROCRYSTALLINE | 2030-12-01 |
| Eli Lilly and Company | JAYPIRCA | pirtobrutinib | 0002-6902 | CROSCARMELLOSE SODIUM | 2030-12-01 |
| Eli Lilly and Company | JAYPIRCA | pirtobrutinib | 0002-6902 | FD&C BLUE NO. 2 ALUMINUM LAKE | 2030-12-01 |
| Eli Lilly and Company | JAYPIRCA | pirtobrutinib | 0002-6902 | HYPROMELLOSE | 2030-12-01 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for PIRTOBRUTINIB
Excipient focus: CELLULOSE, MICROCRYSTALLINE
PIRTOBRUTINIB drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | pirtobrutinib | 0002-6902 |
| >Company | >Ingredient | >NDC |
PIRTOBRUTINIB drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
PIRTOBRUTINIB drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | pirtobrutinib | 0002-6902 |
| >Company | >Ingredient | >NDC |
PIRTOBRUTINIB drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 2 ALUMINUM LAKE
PIRTOBRUTINIB drug variants containing FD&C BLUE NO. 2 ALUMINUM LAKE
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | pirtobrutinib | 0002-6902 |
| >Company | >Ingredient | >NDC |
PIRTOBRUTINIB drug variants not containing FD&C BLUE NO. 2 ALUMINUM LAKE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
PIRTOBRUTINIB drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | pirtobrutinib | 0002-6902 |
| >Company | >Ingredient | >NDC |
PIRTOBRUTINIB drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE ACETATE SUCCINATE 12070923
PIRTOBRUTINIB drug variants containing HYPROMELLOSE ACETATE SUCCINATE 12070923
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | pirtobrutinib | 0002-6902 |
| >Company | >Ingredient | >NDC |
PIRTOBRUTINIB drug variants not containing HYPROMELLOSE ACETATE SUCCINATE 12070923
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
PIRTOBRUTINIB drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | pirtobrutinib | 0002-6902 |
| >Company | >Ingredient | >NDC |
PIRTOBRUTINIB drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
PIRTOBRUTINIB drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | pirtobrutinib | 0002-6902 |
| >Company | >Ingredient | >NDC |
PIRTOBRUTINIB drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
PIRTOBRUTINIB drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | pirtobrutinib | 0002-6902 |
| >Company | >Ingredient | >NDC |
PIRTOBRUTINIB drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
PIRTOBRUTINIB drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | pirtobrutinib | 0002-6902 |
| >Company | >Ingredient | >NDC |
PIRTOBRUTINIB drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIACETIN
PIRTOBRUTINIB drug variants containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | pirtobrutinib | 0002-6902 |
| >Company | >Ingredient | >NDC |
PIRTOBRUTINIB drug variants not containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
